Tech Company Financing Transactions

Cequent Pharmaceuticals Funding Round

Cequent Pharmaceuticals closed a $2.7 million funding round on 12/31/2009. Investors included Amidzad Partners, New England Partners and Novartis Venture Fund.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

1 Kendall Sq. Building 700 First Floor
Cambridge, MA 02139
USA

Phone

(617) 995-7940

Website

www.cequentpharma.com

Email Address

[email protected]

Overview

Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Peter Parker

        

Chief Financial Officer

Lisa Velardo

        

VP - Bus. Development

Susie Truong

        

VP - R & D

Johannes Fruehauf

        

VP - Regulatory Affairs

Pamela Fekete

        

Browse more venture capital transactions:

Prev: 12/31/2009: Calistoga Pharmaceuticals venture capital transaction
Next: 12/31/2009: AtheroMed venture capital transaction

Share this article

About Database of VC Transactions

Our team works diligently to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary